April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD. This content was developed ...
Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa. This content was developed independently and is not ...
This morning, experts delivered "short and sweet" updates on treatment strategies for common dermatologic conditions. This content was developed independently and is not endorsed by the American ...
Despite its relevance to prognosis and treatment response, baseline disease duration is inconsistently reported in phase 3 clinical trials for chronic spontaneous urticaria (CSU), ...
New research is helping to change the way investigators and clinicians think about and treat Richter transformation (RT) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic ...
Experts at the 2026 AAD Annual Meeting urged dermatologists to engage in advocacy to protect practices and patient access amid growing challenges. Klint Peebles, MD, FAAD, a dermatologist with the Mid ...
Topical immunotherapy remains an effective, affordable option for alopecia areata, with long-term control seen in multimodal treatment approaches. Topical immunotherapy continues to have a significant ...
Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...
Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous squamous cell carcinoma (CSCC) ...
The study covers the period of 2015-2019 in Germany, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival ...
Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. HS, a chronic, recurrent ...
The big question in administration of bispecific antibodies these days is how quickly they can move to the outpatient setting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results